TLIS | Talis Biomedical Corporation Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.7200 - 1.7200
52 Week Range	1.3700 - 9.60
Beta	1.70
Implied Volatility	514.89%
IV Rank	35.16%
Day's Volume	100
Average Volume	27,356
Shares Outstanding	1,822,820
Market Cap	3,135,250
Sector	Healthcare
Industry	Medical - Devices
IPO Date	2021-02-12

Valuation
Profitability
Growth
Health
P/E Ratio	-0.06
Forward P/E Ratio	N/A
EPS	-28.02
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	99
Country	USA
Website	TLIS

Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.

TLIS's peers: AEMD, BBLG, BJDX, MODD, BSGM, BVS, CTKB, ECOR, HSDT, IINN, IRIX, MYO, NSPR, NSYS, NURO, NUWE, NVNO, OWLT, QTRX, RPID, RSLS, RXST, TIVC, VERO, VVOS, HSCS

*Chart delayed

Analyzing fundamentals for TLIS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is weak. For more detailed analysis please see TLIS Fundamentals page.

Watching at TLIS technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on TLIS Technicals page.